News | September 22, 2022
JB Pharma witness 20% growth in August 2022: IQVIA
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Aster Pharmacy will be operated by GD Assist Limited in Bangladesh.
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The ANDA was filed as 'First to File' submission on NCE-1 date.
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
Subscribe To Our Newsletter & Stay Updated
